Lyrus, No. 22, 7th Cross, Jaibharath Nagar, Bangalore (2026)

16/02/2026

Heart Health Month | February
February is observed globally as Heart Health Month, a reminder that cardiovascular health remains one of the most critical challenges in modern healthcare.
Heart disease continues to be a leading cause of morbidity worldwide—driven by lifestyle factors, metabolic disorders, ageing populations, and unmet preventive care needs. Addressing this challenge requires more than awareness; it demands robust science, innovation in formulation, and scalable therapeutic solutions.
At Lyrus, we believe meaningful impact begins when we think strategically about patient needs, design formulations with scientific rigour, and deliver quality-driven solutions that support long-term cardiovascular health. As a science-led CDMO, we partner with pharmaceutical companies to advance research, development, and manufacturing of differentiated therapies across cardio-metabolic and preventive healthcare domains.
This Heart Health Month, we reaffirm our commitment to enabling better outcomes through innovation, collaboration, and responsible pharmaceutical development.

&D

14/02/2026

We are proud to congratulate Bangarayya mathamsetti on being recognised as a RISING STAR at the hashtag Leadership Awards2026, held on 13th & 14th February 2026.
This recognition is a testament to his dedication, leadership mindset, and commitment to excellence.
At Lyrus, leadership is not defined by hierarchy — it is defined by the ability to think beyond boundaries, design solutions with scientific rigour, and deliver measurable impact. Bangarayya exemplifies this spirit through his performance, ownership, and drive to create value.
As a science-led CDMO, we believe our people are our strongest differentiator. When emerging leaders rise, the organisation advances — in capability, in culture, and in global impact.
Congratulations on this well-deserved achievement. Wishing you continued growth and many more milestones ahead.
For professionals who aspire to grow in a high-performance R&D environment connect with us at hr@lyruslife.com

11/02/2026

On International Day of Women and Girls in Science, we recognise the women scientists who are shaping the future of healthcare through curiosity, rigour, and purpose.
Across pharmaceutical research and development, women are driving innovation in formulation science, analytical research, clinical development, and quality excellence. Their work enables safer, more effective therapies—and strengthens global health systems.
At Lyrus, we believe progress begins when we think inclusively, design with scientific depth, and deliver solutions that truly matter. Empowering women in science is not just about representation—it is about building better science, stronger teams, and more impactful outcomes for patients worldwide.
As a science-led CDMO, we remain committed to fostering an environment where women researchers and professionals can grow, lead, and innovate across the pharmaceutical value chain.
We look forward to collaborating with organisations and partners who share this commitment to advancing science through diversity and excellence.
For partnerships or collaborations, write to bd@lyruslife.com

&D

09/02/2026

Supporting Smoke-Free Futures on World Quit Smoking Day 🚭
Did you know? Smoking claims over 8 million lives yearly, damaging lungs, heart, and accelerating cancer—yet quitting slashes risks dramatically within months.
Key facts: Ni****ne addiction drives 80% of quit failures, but evidence-based therapies like patches, gums, and inhalers boost success by 50-70%.
Lyrus leads with educational commitment and CDMO prowess: We engineer advanced ni****ne replacement therapies (NRTs), smokeless alternatives, and respiratory formulations using NDDS platforms for optimal absorption and compliance. Our cGMP labs ensure rigorous stability testing, impurity profiling, and regulatory dossiers (eCTD, ANDA) for US/EU markets. From pre-formulation to pilot scale, we partner for impactful, patient-centric solutions.
Empower quits, elevate health. Connect with Lyrus' experts today!

04/02/2026

World Cancer Day: Innovating for a Cancer-Free Future
At Lyrus, a trusted CDMO partner, we're harnessing advanced NDDS and platform technologies to develop targeted, controlled-release formulations for oncology therapies. Our world-class R&D team, backed by cGMP-compliant analytical development and regulatory expertise (eCTD/ANDA), delivers end-to-end solutions—from formulation to pilot scale—for regulated markets like US, Europe, and Australia.
Join us in raising awareness and accelerating breakthroughs. Let's collaborate to transform patient outcomes.

30/01/2026

On January 30, World Neglected Tropical Diseases(NTD) Day, we shine a light on the 1.6 billion people worldwide affected by NTDs—diseases that thrive in resource-limited settings but steal millions of healthy years annually.
At Lyrus, we're bridging the access gap through strategic global alliances, portable drug delivery solutions, and cutting-edge NDDS platforms. Our partnerships with international health organizations enable scalable formulations that withstand harsh logistics—from humid tropics to remote villages—ensuring therapies reach those who need them most.
Together, we're turning innovation into impact. Join us in raising awareness and supporting equitable healthcare.

26/01/2026

On Republic Day, January 26, we celebrate the spirit of India—a nation that embodies unity, resilience, and boundless innovation.
At Lyrus, we're proud to contribute to this legacy through our cutting-edge CDMO operations, pioneering NDDS platforms, and global alliances that advance Indian pharma on the world stage. From formulation excellence to accessible healthcare, we're building a healthier tomorrow, one molecule at a time.
Jai Hind! Let's honour our Constitution's promise of justice, liberty, and equality by driving pharma innovation for all. Share your Republic Day reflections below.

23/01/2026

On Maternal Health Awareness Day, January 23, we focus on the delicate balance of risk-benefit in formulations for pregnancy and lactation—where safety is non-negotiable.
At Lyrus, our CDMO expertise shines through rigorous safety profiling, comprehensive documentation per FDA PLLR guidelines (including risk summaries and lactation data), bioequivalence strategies tailored for vulnerable populations, and ongoing dialogues with regulatory authorities. These steps ensure therapies are not just effective but demonstrably safe, minimizing placental/breast milk transfer risks while maximizing maternal outcomes.
Partnering with us means innovation grounded in evidence—protecting mothers and babies, one formulation at a time. Share your insights on safe pharma design below.

19/01/2026

Empowering Prevention: Cervical Cancer Awareness Month.
This January, Lyrus and our CSR unit, Bothra Foundation, unite in the fight against cervical cancer—organizing regular screening programs to drive early detection and save lives.
In parallel, our CDMO expertise scales complex, patient-centric dosage forms through world-class R&D, in-house pilot manufacturing, and strategic MHRA/FDA-approved alliances for seamless portability to regulated markets like US, Europe, and Africa.
Pharma leaders, partner with us to innovate impactful therapies. Together for healthier futures. &D

14/01/2026

On the eve of harvest festivals like and , we reflect on themes of abundance and renewal—just as Lyrus nurtures niche molecules from innovative labs to global markets. Our journey mirrors this cycle: reaping R&D successes through pilot manufacturing and strategic alliances for patient-centric dosage forms.
Our end-to-end CDMO platform takes complex formulations from dedicated research labs to in-house pilot scale, then leverages portability via MHRA/EU GMP/FDA-approved alliances worldwide. This ensures seamless market access in regulated regions like Europe, US, Australia, and Africa, prioritizing innovative, patient-centric dosage forms.
B2B partners, let's collaborate on your next breakthrough. DM for discussions on NDDS or generics development.

12/01/2026

On National Youth Day, India honours the birth anniversary of Swami Vivekananda and celebrates the power of young minds to shape the nation’s future. At Lyrus, this spirit lives in every young scientist, analyst and regulatory professional who is pushing the boundaries of drug delivery, formulation science and quality.

From NDDS and controlled release technologies to analytical development and dossier preparation for global markets, our teams demonstrate how empowered youth can convert ideas into impactful healthcare solutions. Their curiosity, courage and commitment are helping build a healthier, more self-reliant India and creating value for patients worldwide.

To the next generation of pharma innovators: your skills, integrity and resilience will define the future of global healthcare. Keep learning, keep questioning, and keep building solutions that matter.

09/01/2026

On Pravasi Bharatiya Diwas, Lyrus celebrates the global Indian scientific and healthcare community whose ideas, research and leadership are improving patient outcomes across continents.
As a Bengaluru-headquartered, research-led CDMO, Lyrus partners with pharma companies worldwide to develop differentiated formulations, novel drug delivery systems and specialty products for highly regulated markets. From pre-formulation and analytical development to pilot, exhibit batches and regulatory dossiers, our teams work seamlessly with global and diaspora-led organisations to accelerate development while ensuring quality and compliance.
To every NRI and PIO scientist, physician, regulator and business leader contributing to a healthier, more resilient world – Lyrus salutes your impact and invites you to collaborate in building the next generation of therapies from India, for global patients.

Lyrus

16/02/2026

14/02/2026

11/02/2026

09/02/2026

04/02/2026

30/01/2026

26/01/2026

23/01/2026

19/01/2026

14/01/2026

12/01/2026

09/01/2026

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category